BRPI0309126A8 - Métodos para tratar condições relacionadas com tweak - Google Patents

Métodos para tratar condições relacionadas com tweak

Info

Publication number
BRPI0309126A8
BRPI0309126A8 BRPI0309126A BR0309126A BRPI0309126A8 BR PI0309126 A8 BRPI0309126 A8 BR PI0309126A8 BR PI0309126 A BRPI0309126 A BR PI0309126A BR 0309126 A BR0309126 A BR 0309126A BR PI0309126 A8 BRPI0309126 A8 BR PI0309126A8
Authority
BR
Brazil
Prior art keywords
tweak
methods
antagonists
agonists
provides methods
Prior art date
Application number
BRPI0309126A
Other languages
English (en)
Other versions
BR0309126A (pt
Inventor
Burkly Linda
Jakubowski Aniela
Zheng Timothy
Hahm Kyungmin
Original Assignee
Biogen Idec Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Ma Inc filed Critical Biogen Idec Inc
Publication of BR0309126A publication Critical patent/BR0309126A/pt
Publication of BRPI0309126A8 publication Critical patent/BRPI0309126A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)

Abstract

USOS DE ANTAGONISTAS DE TWEAK, BEM COMO MÉTODO PARA MODULAR PROLIFERAÇÃO OU DIFERENCIAÇÃO CELULAR DE UMA CÉLULA IN VITRO. A presente invenção refere-se a métodos e agentes para o tratamento de condições relacionadas com TWEAK, inclusive doenças cardíacas, hepáticas, renais, pulmonares, de adipose, dos músculos esqueléticos, neuronal, ósseas e cartilaginosas. A invenção também proporciona métodos para indentificar agonistas e antagonistas de TWEAK para o tratamento de condições relacionadas com TWEAK. Adicionalmente, a invenção proporciona animais transgênicos que expressam um DNA exógeno codificando um polipeptídeo TWEAK, ou fragmentos, análogos, ou muteínas do mesmo e métodos para usar semelhantes animais para identificar agonistas e antagonistas de TWEAK. A invenção proporciona ainda métodos para diagnosticar uma doença com base na expressão de TWEAK. A invenção também proporciona métodos para afetar a diferenciação celular de células progenitoras usando polipeptídeos TWEAK, agonistas ou antagonistas.
BRPI0309126A 2002-04-09 2003-04-09 Métodos para tratar condições relacionadas com tweak BRPI0309126A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37161102P 2002-04-09 2002-04-09
PCT/US2003/011350 WO2003086311A2 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions

Publications (2)

Publication Number Publication Date
BR0309126A BR0309126A (pt) 2005-06-07
BRPI0309126A8 true BRPI0309126A8 (pt) 2017-03-07

Family

ID=29250708

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309126A BRPI0309126A8 (pt) 2002-04-09 2003-04-09 Métodos para tratar condições relacionadas com tweak

Country Status (20)

Country Link
US (5) US20060240004A1 (pt)
EP (4) EP1997512B1 (pt)
JP (4) JP2005536455A (pt)
KR (2) KR101174214B1 (pt)
CN (5) CN103536916B (pt)
AU (1) AU2003224950B2 (pt)
BR (1) BRPI0309126A8 (pt)
CA (2) CA2887716C (pt)
DK (1) DK1997512T3 (pt)
EA (1) EA011607B1 (pt)
ES (1) ES2444121T3 (pt)
HK (1) HK1127545A1 (pt)
IL (3) IL164352A0 (pt)
MX (2) MXPA04009683A (pt)
NO (2) NO334266B1 (pt)
NZ (2) NZ536348A (pt)
PT (1) PT1997512E (pt)
SI (1) SI1997512T1 (pt)
WO (1) WO2003086311A2 (pt)
ZA (1) ZA200408073B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
BR0007556A (pt) 1999-01-15 2001-10-23 Biogen Inc Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
EP1363657A2 (en) 2000-05-08 2003-11-26 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
AU2011239311B2 (en) * 2005-02-17 2014-05-22 Biogen Ma Inc. Treating Neurological Disorders
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
EP1764109A1 (de) * 2005-05-24 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2010005519A1 (en) * 2008-06-30 2010-01-14 University Of Pennsylvania Fn14/trail fusion proteins
WO2010019234A1 (en) * 2008-08-12 2010-02-18 Ihc Intellectual Asset Management, Llc Analysis of genetic markers for peripartum cardiomyopathy
JP5161718B2 (ja) * 2008-09-25 2013-03-13 株式会社ゲノム創薬研究所 肝障害モデル動物、及びそれを用いた肝障害を改善又は予防する、薬剤若しくは食品素材のスクリーニング方法
MX2011007936A (es) * 2009-01-30 2011-08-17 Biogen Idec Inc Metodos para regeneracion de tejido pancreatico.
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
WO2011097500A2 (en) * 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
CA2809632A1 (en) 2010-10-05 2012-04-12 Monika Baehner Antibodies against human tweak and uses thereof
RU2462222C1 (ru) * 2011-07-11 2012-09-27 Наталья Николаевна Молчанова Способ лечения больных артериальной гипертонией с метаболическими нарушениями
SG2014010334A (en) * 2011-08-23 2014-06-27 Transbio Ltd Fn14 binding proteins and uses thereof
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
CN107106637B (zh) * 2014-08-21 2021-06-25 康德生物医疗技术公司 用于疾病预防和治疗的方法和组合物
WO2016061632A1 (en) * 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
KR101881531B1 (ko) * 2016-11-25 2018-07-25 고려대학교 산학협력단 폴리-2-하이드록시에틸 메타아크릴레이트를 이용한 사이토카인의 발현능이 증가된 줄기세포의 제조방법
CN113616777A (zh) * 2021-08-18 2021-11-09 中山大学附属第三医院（中山大学肝脏病医院） 基于主要尿蛋白改善内质网应激的转化应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5200313A (en) 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US4921698A (en) 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AT396939B (de) 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1995014772A1 (fr) 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
EP0815202B1 (en) 1994-12-13 2007-02-21 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EP1591530B8 (en) 1996-08-07 2015-04-22 Biogen Idec MA Inc. A tumor necrosis factor related ligand
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
WO2002095010A2 (en) 2001-03-21 2002-11-28 Human Genome Sciences, Inc. Human secreted proteins
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
AU762959B2 (en) 1997-09-18 2003-07-10 Genentech Inc. DcR3 polypeptide, A TNFR homolog
CA2305713A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
US20020072089A1 (en) 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO1999059614A1 (en) 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
CA2329072A1 (en) 1998-05-29 1999-12-02 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
JP2002527096A (ja) 1998-10-16 2002-08-27 イミュネックス・コーポレーション 血小板の活性化及び補充の阻害剤
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
MXPA01006330A (es) 1998-12-22 2002-07-02 Genentech Inc Metodos y composiciones para inhibir el crecimiento de celulas neoplasticas.
BR0007556A (pt) * 1999-01-15 2001-10-23 Biogen Inc Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
DK1607402T3 (da) 1999-03-08 2007-04-16 Genentech Inc Sammensætninger og fremgangsmåder til tumorbehandling
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
KR20050004240A (ko) 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
EP1248645B1 (en) 2000-01-03 2007-04-18 Tr Associates, L.L.C. Novel chimeric proteins and their use
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
ATE358718T1 (de) 2000-02-25 2007-04-15 Immunex Corp Integrin antagonisten
EP1363657A2 (en) 2000-05-08 2003-11-26 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
CA2422095A1 (en) * 2000-09-14 2002-03-21 Biogen, Inc. Tweak receptor agonists as anti-angiogenic agents
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
JP4344519B2 (ja) 2000-12-28 2009-10-14 旭化成ファーマ株式会社 ＮＦ−κＢ活性化遺伝子
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040091473A1 (en) 2001-07-27 2004-05-13 Dubose Robert F. Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
EP1478740A2 (en) 2001-07-27 2004-11-24 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2003070763A1 (en) 2001-08-16 2003-08-28 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
EP1599607A2 (en) 2003-03-04 2005-11-30 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
US7482430B2 (en) 2003-07-24 2009-01-27 Amgen Inc. Compositions and methods relating to multimeric and oligomeric soluble fragments of the TWEAK receptor
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
CA2587018A1 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
CN102225200A (zh) 2005-03-07 2011-10-26 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2069521A4 (en) 2006-10-16 2009-12-16 Biogen Idec Inc BIOMARKERS OF SCLEROSIS IN PLATE
BRPI0912198A2 (pt) * 2008-05-15 2019-09-24 Biogen Idec Inc anticorpos anti-fn14 e usos dos mesmos
WO2010085648A2 (en) 2009-01-23 2010-07-29 Linda Burkly C Methods for reducing radiation-induced tissue damage
MX2011007936A (es) 2009-01-30 2011-08-17 Biogen Idec Inc Metodos para regeneracion de tejido pancreatico.
CA2809632A1 (en) 2010-10-05 2012-04-12 Monika Baehner Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
EP2301577A3 (en) 2012-08-08
IL230158B (en) 2018-06-28
US20060240004A1 (en) 2006-10-26
EP1494713A2 (en) 2005-01-12
CN103536916A (zh) 2014-01-29
US20120015024A1 (en) 2012-01-19
NO20131617L (no) 2005-01-07
NO20044857L (no) 2005-01-07
SI1997512T1 (sl) 2014-03-31
CN101683520A (zh) 2010-03-31
MXPA04009683A (es) 2005-01-11
MX352180B (es) 2017-11-13
AU2003224950B2 (en) 2006-09-14
DK1997512T3 (da) 2014-01-27
US9011859B2 (en) 2015-04-21
IL164352A0 (en) 2005-12-18
EP1494713A4 (en) 2005-12-28
CA2480745A1 (en) 2003-10-23
KR101000842B1 (ko) 2010-12-14
NZ548701A (en) 2008-03-28
EP2301577A2 (en) 2011-03-30
EP2301578A3 (en) 2012-08-08
ES2444121T3 (es) 2014-02-24
JP2012021014A (ja) 2012-02-02
KR20040111500A (ko) 2004-12-31
CA2887716C (en) 2017-01-24
JP5603040B2 (ja) 2014-10-08
CN103536916B (zh) 2016-08-17
NO338778B1 (no) 2016-10-17
EP2301578A2 (en) 2011-03-30
CN102793921A (zh) 2012-11-28
CN1658901A (zh) 2005-08-24
PT1997512E (pt) 2014-02-20
EP1997512A3 (en) 2009-03-11
JP2009286793A (ja) 2009-12-10
CA2887716A1 (en) 2003-10-23
EA200401329A1 (ru) 2005-10-27
WO2003086311A2 (en) 2003-10-23
NZ536348A (en) 2007-05-31
JP2014132004A (ja) 2014-07-17
AU2003224950A1 (en) 2003-10-27
KR101174214B1 (ko) 2012-08-14
JP5916776B2 (ja) 2016-05-11
NO334266B1 (no) 2014-01-27
IL164352A (en) 2016-08-31
CN106421778A (zh) 2017-02-22
JP2005536455A (ja) 2005-12-02
ZA200408073B (en) 2006-06-28
KR20100099348A (ko) 2010-09-10
BR0309126A (pt) 2005-06-07
EP1997512B1 (en) 2013-12-04
US20090311313A1 (en) 2009-12-17
HK1127545A1 (en) 2009-10-02
EP1997512A2 (en) 2008-12-03
WO2003086311A3 (en) 2004-06-24
US8506958B2 (en) 2013-08-13
US20150291688A1 (en) 2015-10-15
EA011607B1 (ru) 2009-04-28
US20130216496A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
BRPI0309126A8 (pt) Métodos para tratar condições relacionadas com tweak
Vieira et al. Advancements to the axolotl model for regeneration and aging
Emmerson et al. Salivary glands regenerate after radiation injury through SOX2‐mediated secretory cell replacement
Godwin et al. Chasing the recipe for a pro-regenerative immune system
Huang et al. Molecular regulation of tendon cell fate during development
Bragulla et al. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia
Hall Bones and cartilage: developmental and evolutionary skeletal biology
Lust et al. A comparative perspective on brain regeneration in amphibians and teleost fish
BR0209563A (pt) ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
Roy et al. Limb regeneration in axolotl: is it superhealing?
RU2014136711A (ru) Стромальные стволовые клетки
Lv et al. Using RNA‐Seq to explore the repair mechanism of the three methods and three‐acupoint technique on DRGs in Sciatic nerve injured rats
Davidian et al. Inducing vertebrate limb regeneration: A review of past advances and future outlook
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
Boilly et al. Production in vitro by spinal cord of growth factor (s) acting on newt limb regeneration: influence of regeneration of the nerve fibers
Oster et al. Fast and reliable dissection of porcine parathyroid glands—A protocol for molecular and histological analyses
Weber et al. The role of jab1, a putative downstream effector of the neurotrophic cytokine macrophage migration inhibitory factor (MIF) in zebrafish inner ear hair cell development
Anup et al. Embracing ethical research: Implementing the 3R principles into fracture healing research for sustainable scientific progress
Karahisar Turan et al. Investigation of axonal regeneration of Triturus ivanbureschi by using physiological and proteomic strategies
Hyun et al. Rethinking the blastema
BRPI0512342A (pt) métodos para aumento ósseo
CN101138630A (zh) 用于修复神经损伤的纤维蛋白胶组合物及其方法
Abreu et al. Experimental model of skeletal muscle laceration in rats
Liu et al. Olfactory-ensheathing cells promote physiological repair of injured recurrent laryngeal nerves and functional recovery of glottises in dogs
Tyrnenopoulou et al. Clinical application of adipose-derived stromal vascular fraction in 3 Thoroughbred horses with superficial digital flexor tendonitis: Case Report

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25I Requirement for requested change of headquarter

Owner name: BIOGEN MA INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25G Requested change of headquarter approved

Owner name: BIOGEN MA INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]